Regeneron Sanofi report Japanese alirocumab data

Regeneron Pharmaceuticals Inc. NASDAQREGN and partner Sanofi EuronextSAN; NYSESNY said subcutaneous alirocumab REGN727 given every other week in combination with statin therapy met the primary endpoint vs. placebo in a Japanese Phase II trial to treat prim...